Genmab A/S Stock Deutsche Boerse AG
Stocks
GE9
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Tradegate
02:41:14 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 285.80 EUR | +0.28% |
|
+0.04% | +5.61% |
| 12:32am | Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN | FW |
| 09-03 | Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo | FW |
| Market Cap | 128B 19.89B 17.1B 16.09B 14.69B 27.47B 1,881B 27.55B 191B 73.73B 963B 74.69B 73.06B 3,068B | P/E 2026 * |
27.1x | P/E 2027 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise Value | 147B 22.88B 19.67B 18.5B 16.89B 31.59B 2,163B 31.69B 219B 84.8B 1,108B 85.91B 84.03B 3,529B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 4.12x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Copenhagen
| GMAB | Delayed | |
CBOE
| GMABc | Real-time | |
|
Mexican S.E.
| GMAB N | End-of-day quote | |
|
Tradegate
| GE9 | Real-time | |
|
OTC Markets
| GNMSF | Delayed | |
|
London S.E.
| 0MGB | Delayed | |
|
Xetra
| GE9 | End-of-day quote | |
|
Xetra
| GE9 | Delayed | |
|
Deutsche Boerse AG
| GE9 | Delayed | |
|
CBOE
| 0MGB | Real-time | |
|
Börse Stuttgart
| GE9 | Delayed | |
|
Boerse Muenchen
| GE9 | Real-time | |
|
Wiener Boerse
| GMAB | End-of-day quote |
Last Transcript : Genmab A/S
| 1 day | +0.28% | ||
| 1 week | +0.04% | ||
| Current month | +0.35% | ||
| 1 month | +7.69% | ||
| 3 months | +33.27% | ||
| 6 months | +21.75% | ||
| Current year | +5.61% |
| 1 week | 284.4 |  | 295.1 |
| 1 month | 262.8 | | 295.1 |
| Current year | 202.8 | | 303.8 |
| 1 year | 202.8 | | 303.8 |
| 3 years | 155.95 | | 361.7 |
| 5 years | 155.95 | | 445.1 |
| 10 years | 106.25 | | 445.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.28% | +0.04% | - | - | 19.89B | |
| -0.38% | -0.99% | +42.69% | +100.85% | 67.82B | |
| -2.71% | -0.71% | +35.89% | +81.43% | 63.22B | |
| -0.31% | +3.67% | -12.96% | +374.95% | 27.58B | |
| +0.86% | +2.12% | -7.74% | -13.34% | 26.06B | |
| +0.87% | -1.21% | +25.40% | +14.47% | 25.38B | |
| -1.11% | +0.90% | +22.24% | -18.50% | 19.89B | |
| +1.15% | -5.02% | +219.82% | +379.02% | 17.4B | |
| -1.26% | -0.90% | -7.81% | +521.51% | 14.95B | |
| -0.20% | +8.00% | +55.78% | +167.98% | 14.62B | |
| Average | -0.26% | +1.67% | +41.48% | +178.71% | 30.77B | |
| Weighted average by Cap. | -0.60% | +0.90% | +36.89% | +140.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.95B 4.5B 3.87B 3.64B 3.33B 6.22B 426B 6.24B 43.2B 16.7B 218B 16.92B 16.55B 695B | 33.71B 5.25B 4.51B 4.24B 3.87B 7.24B 496B 7.27B 50.31B 19.45B 254B 19.7B 19.27B 809B |
| Net income | 4.93B 767M 659M 620M 566M 1.06B 72.5B 1.06B 7.35B 2.84B 37.13B 2.88B 2.82B 118B | 7.16B 1.11B 958M 901M 823M 1.54B 105B 1.54B 10.69B 4.13B 53.97B 4.19B 4.09B 172B |
| Net Debt | 19.19B 2.99B 2.57B 2.42B 2.21B 4.12B 282B 4.14B 28.64B 11.07B 145B 11.22B 10.97B 461B | 11.03B 1.72B 1.48B 1.39B 1.27B 2.37B 162B 2.38B 16.45B 6.36B 83.09B 6.44B 6.3B 265B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | €284.40 | -0.21% | 0 |
| 26-09-07 | €285.00 | -0.90% | 0 |
| 26-09-04 | €287.60 | -1.98% | 0 |
| 26-09-03 | €293.40 | -0.58% | 0 |
| 26-09-02 | €295.10 | +3.80% | 3 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GE9 Stock
Select your edition
All financial news and data tailored to specific country editions
